Fig. 3

FGF21 suppresses the expression of atrophic factors and NF-kB activation in TNFα-treated myotubes. Myotubes at 2 days of differentiation were treated with 100 ng/mL TNFα in the presence or absence of FGF21 for 24 h. (a) Myotube morphology was observed at 100x magnification. The levels of (b) mRNA and (c-d) protein for MuRF1 and Atrogin-1 in C2C12 myotubes. (e) The levels of p-eIF2α/eIF2α protein in C2C12 myotubes. (f) NF-κB activation in C2C12 myotubes. Results are means ± SEM *P < 0.05, **P < 0.01, ***P < 0.001 compared with TNFα-treated myotubes